Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched with activated cytotoxic effectors predict early relapse and quiescent/naive T-cells predicting remission.”
Title: Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance
Authors: Ross S. Firestone, Anish K. Simhal, Devin McAvoy, Eric M. Jurgens, Juan-Jose Garcés, David Nemirovsky, Andriy Derkach, Kylee H. Maclachlan, Malin Hultcrantz, Sham Mailankody, Urvi A. Shah, Carlyn R. Tan, Neha Korde, Hani Hassoun, Sridevi Rajeeve, Hamza Hashmi, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Benjamin T. Diamond, Francesco Maura, Kinga Hosszu, David J. Chung, Ola Landgren, Saad Z. Usmani, Alexander M. Lesokhin
You can read the Full Article on Clinical Cancer Research.
You can find more posts featuring Robert Orlowski on OncoDaily.
